IMAGe Syndrome: Comprehensive Research Report

1. Disease Information

Overview. IMAGe syndrome is a rare, multisystem, imprinted genetic disorder whose name is an acronym for its four cardinal features: Intrauterine growth restriction, Metaphyseal dysplasia, Adrenal hypoplasia congenita, and Genital anomalies (in males). It typically presents in the neonatal period with severe, potentially life-threatening primary adrenal insufficiency superimposed on prenatal-onset growth failure and skeletal dysplasia. First delineated clinically by Vilain et al. in 1999 (PMID: not indexed in this search; described in J Clin Endocrinol Metab), the molecular cause — heterozygous, maternally inherited, gain-of-function missense variants in CDKN1C — was identified in 2012 (Nature Genetics; PMID: cited below).

Key identifiers: - OMIM: #614732 — Intrauterine Growth Retardation, Metaphyseal Dysplasia, Adrenal Hypoplasia Congenita, and Genital Anomalies; IMAGE (omim.org/entry/614732) - OMIM (allelic recessive form, POLE1-related): #618336 - MONDO: MONDO:0013873 (monarchinitiative.org/MONDO:0013873) - Orphanet: ORPHA:85173 - GeneReviews: Schrier Vergano SA, Deardorff MA. IMAGe Syndrome. NCBI Bookshelf NBK190103, updated 5 August 2021 (ncbi.nlm.nih.gov/books/NBK190103) - Causal gene: CDKN1C (HGNC:1785; OMIM 600856), chromosome 11p15.4 (within the imprinted 11p15.5 domain) - GTR:* C1846009

Synonyms: IMAGe association; Intrauterine Growth Retardation, Metaphyseal Dysplasia, Adrenal Hypoplasia Congenita, and Genital Anomalies syndrome.

Data source note: Nearly all published knowledge is derived from aggregated case reports/case series (individual-patient-level data pooled across publications) rather than large cohort or EHR-based studies, reflecting the disorder's extreme rarity — as of the 2021 GeneReviews update, only 31 affected individuals from 19 families had been documented worldwide (22 of 31 male, reflecting ascertainment bias from visible genital anomalies) [GeneReviews NBK190103].

2. Etiology

Primary cause — genetic, imprinted, gain-of-function. IMAGe syndrome is caused by heterozygous missense pathogenic variants clustered in an 8-amino-acid region of CDKN1C's PCNA-binding domain (approximately residues 271/274–279), and the phenotype manifests only when the variant is maternally inherited, owing to genomic imprinting of CDKN1C (paternal allele normally silenced; only the maternal allele is expressed). Paternal transmission produces an unaffected carrier — de facto autosomal dominant inheritance restricted to the maternal line.

"IMAGe syndrome is caused by gain-of-function pathogenic missense variants in the CDKN1C region encoding the PCNA-binding domain (amino acids 271-279) of the maternal allele, which cause loss of PCNA binding and pathogenic CDKN1C gain of function." — GeneReviews (NBK190103)

Known recurrent pathogenic variants include p.Ile272Ser (c.815T>G), p.Asp274Asn (c.820G>A), p.Phe276Val (c.826T>G), p.Arg279Pro (c.836G>C), p.Arg279Leu (c.836G>T), and p.Arg279Ser (c.835C>A) (PMC3787065, PMC4389716, Nature Genetics ng.2275).

A distinct, allelic, recessive cause — POLE1/POLE. A minority of IMAGe-like cases (sometimes termed "IMAGe syndrome with immunodeficiency," IMAGe-I; OMIM #618336) result from biallelic hypomorphic variants in POLE1/POLE (DNA polymerase epsilon catalytic subunit, chromosome 12q24), often a shared intronic splice-altering variant (c.1686+32C>G) in trans with a loss-of-function allele, causing cellular Pol ε deficiency and delayed S-phase progression (Logan et al., AJHG 2018, cell.com/ajhg S0002-9297(18)30400-2; Pachlopnik Schmid et al., PMC4630961). This recessive form adds variable immunodeficiency (lymphocyte deficiency), and sometimes craniosynostosis and cleft palate, to the classic tetrad.

Risk factors: - Genetic: A maternal CDKN1C PCNA-binding-domain variant is both necessary and sufficient; there is no known variable penetrance modifier reported for the dominant CDKN1C form (adrenal insufficiency described as "fully penetrant" in maternally-inherited cases). For the recessive POLE1 form, biallelic inheritance (often via a common founder-like intronic variant) is required. - Environmental/other: No environmental, infectious, lifestyle, or exposure-related risk factors have been reported — this is a purely monogenic/imprinting disorder with no described gene-environment interaction literature.

Protective factors: None identified in the literature; not applicable to this class of highly penetrant, single-gene, imprinted disorder.

3. Phenotypes

All data below are drawn from the GeneReviews cohort synthesis (31 individuals/19 families) and the founding clinical/molecular literature.

Growth

• Intrauterine growth restriction: present in essentially all neonates; birth weights −2 to −4 SD. HP:0001511 (Intrauterine growth retardation)
• Postnatal short stature: continues after birth, height −2.7 to −6.5 SD. HP:0004322 (Short stature)
• Frequency: universal (100% of documented cases)
• Onset: prenatal; persists lifelong
• Course: generally stable/non-progressive after infancy, though some individuals are considered for growth hormone therapy

Skeletal ("Metaphyseal dysplasia")

• Metaphyseal and epiphyseal dysplasia of long bones. HP:0003006 (Metaphyseal dysplasia) / HP:0010602 (Abnormality of epiphysis morphology)
• Delayed bone age — the most common radiologic finding
• Scoliosis (HP:0002650) and osteoporosis (HP:0000939) in a subset
• Frequency: skeletal abnormality in essentially all affected individuals, but radiologic evidence often not apparent until roughly age 5 years — subtle/absent in early infancy (age-dependent expressivity)
• Severity: variable, generally mild-to-moderate

Adrenal (Adrenal hypoplasia congenita — most severe feature)

• Presents as life-threatening primary adrenal insufficiency/adrenal crisis in the first week to month of life: vomiting, feeding difficulty, dehydration, severe hypoglycemia, shock. HP:0000834 (Adrenocortical insufficiency) / HP:0000835 (Adrenal hypoplasia)
• Laboratory: hyponatremia, hyperkalemia, hypotension, and markedly elevated ACTH (often >1000 pg/mL vs. normal 10–60 pg/mL), producing marked hyperpigmentation (HP:0000953)
• Frequency: essentially universal/fully penetrant in maternally-inherited disease
• Onset: neonatal
• QoL impact: high — untreated adrenal crisis is fatal; lifelong glucocorticoid/mineralocorticoid dependence with need for stress dosing

Genital (males only)

• Bilateral cryptorchidism (HP:0000028), micropenis (HP:0000054), hypospadias, hypogonadotropic hypogonadism (HP:0000044)
• Frequency: nearly universal in affected males; absent in affected females (a defining sex-limited feature)
• QoL impact: requires urologic surgery and, at puberty, testosterone replacement

Craniofacial/dysmorphic

• Frontal bossing (HP:0002007), depressed/broad nasal bridge (HP:0000431), small and/or low-set ears (HP:0008551/HP:0000369), relative macrocephaly
• Generally mild, non-disfiguring

Other reported features

• Hypercalciuria/hypercalcemia, occasionally with nephrocalcinosis or soft-tissue/hepatosplenic calcifications — reported in 8 of 16 assessed individuals (~50%); possibly secondary to sodium chloride supplementation used to treat mineralocorticoid deficiency (PMC4293665; GeneReviews)
• Hypotonia — reported in 6 of 31 documented individuals
• Cognitive outcome: normal in ~94% (15/16 assessed) — reassuring for long-term neurodevelopment in the classic CDKN1C form
• One reported case of rhabdomyosarcoma co-occurring with molecularly confirmed IMAGe syndrome (CDKN1C p.Asp274Asn) — the first such report, of unclear causal significance given p57KIP2's role as a tumor-suppressor/cell-cycle regulator (PMID: 34098225)
• POLE1-related (recessive) cases add: variable immunodeficiency/lymphopenia, occasionally craniosynostosis (HP:0004437) and cleft palate (HP:0000175)

4. Genetic/Molecular Information

Causal gene: CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C, p57^KIP2^), HGNC:1785, OMIM 600856, chromosome 11p15.4, within the imprinted KCNQ1/CDKN1C domain (ICR2)* of the 11p15.5 region that also harbors IGF2/H19 (ICR1). CDKN1C is maternally expressed (paternal allele silenced).

Variant class: Missense, gain-of-function, restricted to the PCNA-binding domain (residues ~271/274–279).

Molecular mechanism: - p57^KIP2^ is "a tight-binding, strong inhibitor of several G1 cyclin/Cdk complexes" — specifically cyclin E–CDK2, cyclin D2–CDK4, and cyclin A–CDK2 (PMC3580416), acting as a negative regulator of the G1-to-S cell-cycle transition. - Normally, phosphorylation of Thr310 by cyclin E/CDK2 creates a docking site for the F-box protein Skp2, targeting p57 for SCF^Skp2^-mediated ubiquitination and proteasomal degradation — this is the physiological "off-switch" that permits cell-cycle progression. - IMAGe-associated PCNA-binding-domain mutations disrupt PCNA binding, which paradoxically and dramatically increases CDKN1C protein stability, preventing normal degradation. - The resulting stabilized p57^KIP2^ protein is a more potent, longer-lived cell-cycle inhibitor, producing a gain-of-function phenotype: excessive suppression of cell proliferation/entry into S phase, manifesting clinically as growth restriction (PMID: 24098681, PMC3787065, PLOS ONE 2013; PMID: 25861374, PMC4389716). - Functional validation: targeted expression of IMAGe-associated CDKN1C mutants in Drosophila eye caused severe growth defects compared with wild-type, and mutant protein decreased cell growth significantly more than wild-type or Beckwith-Wiedemann (loss-of-function) CDKN1C variants (Nature Genetics, ng.2275; PMID: 22609246 is the original 2012 discovery paper by Arboleda et al.).

Allelic disorders (same gene, different variant class/location) — critical for interpretation: | Disorder | CDKN1C variant class | Effect | Phenotype | |---|---|---|---| | IMAGe syndrome | Missense, PCNA-binding domain (271–279), maternal | Gain of function (increased stability) | Growth restriction, adrenal hypoplasia, skeletal dysplasia | | Beckwith-Wiedemann syndrome | Nonsense/truncating/missense outside PCNA domain, maternal | Loss of function | Overgrowth, macroglossia, omphalocele, tumor predisposition | | Silver-Russell-like phenotype | p.Arg279Leu/Ser (PCNA domain) | Gain of function, milder | Growth restriction + SRS-like facial features, without adrenal insufficiency | | IMAGe syndrome with immunodeficiency (IMAGe-I, OMIM #618336) | Biallelic POLE1 (different gene, 12q24) | Loss of Pol ε function | IMAGe features + immunodeficiency |

Modifier genes: None specifically established; phenotypic variability (e.g., partial BWS/IMAGe overlap phenotypes, or IMAGe plus developmental delay/microcephaly) has been reported for specific variants but no discrete modifier locus is characterized (PMC8788247).

Epigenetics: The disease mechanism is intrinsically epigenetic — normal CDKN1C expression is governed by genomic imprinting at the KvDMR1/ICR2 differentially methylated region in 11p15.5; IMAGe syndrome is a paradigm case of an imprinting-dependent Mendelian disorder rather than a classical imprinting-defect (methylation-loss) disorder — the defect here is a coding-sequence gain-of-function variant on the already-expressed maternal allele, not loss of imprinting per se.

Population/allele frequency: Given extreme rarity (single-digit families per variant), IMAGe-causing CDKN1C variants are essentially absent from population databases (gnomAD) — de novo maternal-germline or newly arising variants, or transmitted through unaffected carrier fathers, account for observed pedigrees.

Chromosomal abnormalities: Not a copy-number/structural disorder; no aneuploidy or large CNV mechanism described (distinguishing it from other 11p15.5 imprinting disorders like BWS/Silver-Russell syndrome that can also arise via uniparental disomy or ICR methylation defects).

Suggested ontology terms: HGNC:1785 (CDKN1C); GO:0007050 (cell cycle arrest); GO:0000079 (regulation of cyclin-dependent protein serine/threonine kinase activity); GO:0006511 (ubiquitin-dependent protein catabolic process).

5. Environmental Information

No environmental toxin, radiation, occupational, dietary, or lifestyle risk factor is described in the literature as contributing to IMAGe syndrome causation — consistent with its status as a fully penetrant, imprinted monogenic disorder. No infectious trigger is implicated. The only "environmental" element with disease-relevance is iatrogenic: chronic sodium chloride (salt) supplementation, used therapeutically for mineralocorticoid deficiency, is proposed as a contributor to the hypercalciuria/hypercalcemia seen in roughly half of assessed patients (GeneReviews NBK190103) — a treatment-related rather than causal environmental factor.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular trigger: Maternally inherited missense variant in the CDKN1C PCNA-binding domain (e.g., p.Arg279Pro, p.Phe276Val, p.Asp274Asn).
2. Loss of PCNA interaction → mutant p57^KIP2^ escapes the normal Skp2-SCF ubiquitin-proteasome degradation pathway (loss of Thr310-phosphorylation-dependent turnover) → markedly increased protein half-life/stability.
3. Gain-of-function cell-cycle inhibition: stabilized p57^KIP2^ exerts excess, prolonged inhibition of cyclin E–CDK2, cyclin D2–CDK4, and cyclin A–CDK2 complexes → impaired G1-to-S phase transition → reduced cell proliferation across affected tissues.
4. Tissue-level consequences:
5. Reduced proliferation of growth-plate chondrocytes and osteoblast precursors → metaphyseal/epiphyseal dysplasia, delayed bone age, short stature (skeletal/tissue-scale).
6. Impaired proliferation of adrenocortical progenitor cells during fetal adrenal cortex development → adrenal hypoplasia congenita → primary adrenal insufficiency (organ-scale endocrine failure).
7. Impaired growth of somatic tissues generally → intrauterine and postnatal growth restriction (organism-scale).
8. Disrupted genital tubercle/gonadal development in males (androgen-sensitive tissues appear particularly vulnerable) → cryptorchidism, micropenis, hypogonadotropic hypogonadism; the mechanism for the striking male-limited genital phenotype is not fully elucidated but is thought to reflect tissue-specific sensitivity to excess CDK-inhibitor dosage during a critical androgen-dependent developmental window.
9. Downstream/secondary: chronic glucocorticoid/mineralocorticoid replacement and salt supplementation → possible hypercalciuria/nephrocalcinosis (iatrogenic-mechanistic overlay).

Cellular processes involved: cell-cycle arrest/G1 checkpoint control (GO:0000082, G1/S transition of mitotic cell cycle), protein ubiquitination and proteasomal degradation (GO:0006511), negative regulation of cell proliferation (GO:0008285).

Protein dysfunction class: Not misfolding/aggregation — this is a regulatory gain-of-function via impaired degradation (increased protein stability/half-life), a distinct mechanistic category from the more common loss-of-function disease paradigm.

Biochemical abnormality: Failure of Skp2-SCF-mediated ubiquitination of p57^KIP2^ due to loss of the PCNA-docking interaction required for the normal Thr310-phosphorylation/degradation cascade.

Model-system evidence for mechanism: - Drosophila eye model: transgenic expression of IMAGe-mutant CDKN1C caused significantly greater eye growth defects than wild-type CDKN1C, directly supporting a gain-of-function (not simple loss-of-function or dominant-negative) mechanism (Nature Genetics, ng.2275). - Cell-based (in vitro) assays: IMAGe-mutant p57^KIP2^ shows increased protein half-life, impaired PCNA binding, and impaired S-phase entry compared to wild-type and to BWS-associated (loss-of-function) CDKN1C variants (PMID: 24098681; PMID: 25861374). - Cdkn1c mouse models (relevant mechanistic/comparator system, though modeling the loss-of-function/BWS side of the allelic spectrum): Cdkn1c-null mice show ~20% fetal overgrowth followed by late-gestation growth reversal, placental labyrinth thrombotic lesions and disordered trophoblast architecture, and high perinatal lethality (<10% survival to adulthood) (PMID: 21729874). No published Cdkn1c PCNA-domain "knock-in" mouse fully recapitulating IMAGe (gain-of-function, growth-restricted) phenotype was identified in this search — this appears to be a genuine model-system gap (an IMAGe-specific knock-in mouse has not yet been reported), distinguishing it from the reciprocal BWS knock-in mouse (p57 Cdk-binding-domain knock-in reported by PMID: 27015986). - POLE1 mechanistic arm: patient-derived cells with the recessive splice variant show cellular Pol ε deficiency and delayed S-phase progression, and novel POLE mutations cause aberrant nuclear subcellular localization and increased protein degradation (PMID: 35534205) — a mechanistically distinct but convergent route to impaired DNA replication/growth.

Suggested GO terms: GO:0000082 (G1/S transition of mitotic cell cycle), GO:0045930 (negative regulation of mitotic cell cycle), GO:0031145 (anaphase-promoting complex-dependent catabolic process, related SCF/ubiquitin pathway), GO:0006974 (DNA damage response, for the POLE1 arm).

7. Anatomical Structures Affected

Organ level: - Primary: adrenal cortex (adrenal hypoplasia), skeletal system (long bone metaphyses/epiphyses), external/internal male genitalia and gonads - Secondary: kidney (nephrocalcinosis, secondary to hypercalciuria), spine (scoliosis), skull/face (frontal bossing, craniofacial dysmorphism) - Body systems: endocrine (adrenal, gonadal), skeletal, genitourinary; occasionally immune system (POLE1 subtype)

Tissue/cell level: - Adrenal cortex fetal zone/definitive zone progenitor cells (steroidogenic cells) - Growth-plate chondrocytes and metaphyseal osteoblasts - Testicular/genital tubercle mesenchyme - Suggested UBERON terms: UBERON:0001235 (adrenal cortex), UBERON:0002513 (endochondral bone), UBERON:0000019 (camera-type eye — not relevant here, omit), UBERON:0000992 (gonad), UBERON:0000151 (long bone metaphysis — check UBERON:0003535 metaphysis) - Suggested CL terms: CL:0002095 (adrenal cortex cell), CL:0000058 (chondrocyte)

Subcellular level: - Nucleus (site of p57^KIP2^-cyclin/CDK complex activity and cell-cycle control); GO Cellular Component: GO:0005634 (nucleus), GO:0000307 (cyclin-dependent protein kinase holoenzyme complex) - Ubiquitin-proteasome system components (cytoplasmic and nuclear)

Localization: Bilateral/symmetric adrenal hypoplasia; bilateral cryptorchidism; skeletal changes are typically symmetric/bilateral in the metaphyses of long bones.

8. Temporal Development

• Onset: Congenital/prenatal for growth restriction and skeletal dysplasia (detectable in utero via growth restriction); neonatal onset (first week to month of life) for adrenal crisis — often the presenting, life-threatening event.
• Onset pattern: Acute for adrenal crisis; chronic/static for growth and skeletal features.
• Progression: Skeletal radiologic findings are age-dependent — often subtle or absent in early infancy, becoming apparent by approximately age 5 years. Growth restriction is largely established prenatally/in infancy and remains stable (not classically progressive) thereafter, though final height varies (−2.7 to −6.5 SD).
• Disease course: Chronic, lifelong (adrenal insufficiency requires permanent glucocorticoid/mineralocorticoid replacement); not typically relapsing-remitting.
• Longest follow-up reported: oldest documented affected individual was 26 years old, with normal cognitive development (GeneReviews NBK190103).
• Critical period: The neonatal period is the critical window of vulnerability for undiagnosed/untreated adrenal crisis — early recognition and glucocorticoid/mineralocorticoid initiation is the single most important time-sensitive intervention.
• Reproduction: Two affected females have successfully reproduced; no affected males are known to have reproduced (consistent with hypogonadotropic hypogonadism/genital anomalies in males) (GeneReviews NBK190103).

9. Inheritance and Population

Epidemiology: - Prevalence: Orphanet classifies IMAGe syndrome as affecting fewer than 1 in 1,000,000 individuals (ultra-rare). As of the 2021 GeneReviews update, only 31 affected individuals from 19 families had been documented worldwide — true prevalence is unknown and likely undercounted owing to underrecognition/misdiagnosis (e.g., as congenital adrenal hyperplasia or isolated adrenal hypoplasia). - Incidence: Not established; too rare for population-based incidence estimates.

Inheritance pattern: Autosomal dominant with a strict imprinting/parent-of-origin effect — pathogenic only when maternally transmitted (CDKN1C form). The POLE1-related form is autosomal recessive (biallelic).

Penetrance: Adrenal insufficiency appears fully penetrant in maternally-inherited CDKN1C pathogenic variant carriers.

Expressivity: Variable — e.g., skeletal findings are age-dependent and can be subtle; some CDKN1C PCNA-domain variants (p.Arg279Leu/Ser) produce a milder Silver-Russell-like phenotype without adrenal insufficiency, indicating variant-specific expressivity along a phenotypic spectrum (PMID: 28508599, "IMAGe and Related Undergrowth Syndromes: The Complex Spectrum of Gain-of-Function CDKN1C Mutations").

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Germline mosaicism: Possible — GeneReviews notes that when the mother does not carry the variant in blood, sibling recurrence risk is <1%, reflecting the possibility of maternal germline mosaicism rather than zero risk.

Founder effects: The recessive POLE1 form is notable for multiple unrelated families sharing the same intronic splice variant (c.1686+32C>G) as part of a common haplotype — suggestive of a founder allele, though geographic/ethnic clustering was not detailed in the sources reviewed here.

Consanguinity: Relevant to the recessive POLE1 form (biallelic inheritance), though not specifically highlighted as a risk factor in the sources found; not applicable to the dominant/imprinted CDKN1C form.

Carrier frequency: Not established in population databases given extreme rarity.

Population demographics: - Sex ratio: 22 of 31 documented cases male — attributed to ascertainment bias (genital anomalies in males are more clinically apparent and prompt diagnostic workup), not necessarily a true sex-linked susceptibility difference for adrenal/growth features (both sexes affected equally by the core adrenal/growth/skeletal features; genital anomalies affect only males). - Geographic distribution: No endemic region reported; described in geographically diverse case reports/families (implying panethnic occurrence, though systematic geographic epidemiology has not been performed given rarity). - Age distribution: Predominantly diagnosed in infancy/early childhood; oldest reported case 26 years.

10. Diagnostics

No formal consensus clinical diagnostic criteria exist; diagnosis rests on the combination of suggestive clinical/radiologic findings plus molecular confirmation.

Laboratory tests: - Serum electrolytes (hyponatremia, hyperkalemia during adrenal crisis) - Plasma ACTH (markedly elevated, often >1000 pg/mL; normal 10–60 pg/mL) - Cortisol (low/inappropriately low for degree of stress) - Renin/aldosterone (assessing mineralocorticoid axis) - Serum and urine calcium (hypercalcemia/hypercalciuria surveillance) - Suggested LOINC terms: cortisol serum panels, ACTH plasma panels (specific LOINC codes not resolved in this search — recommend direct LOINC lookup during curation)

Imaging: - Skeletal radiographs: metaphyseal/epiphyseal dysplasia, bone-age assessment (delayed) - Renal ultrasound: nephrocalcinosis surveillance - Adrenal imaging (ultrasound/CT/MRI showing small/hypoplastic adrenal glands) — though imaging can be normal early, and the diagnosis is primarily biochemical/genetic

Genetic testing (primary diagnostic modality): - Single-gene sequence analysis of CDKN1C — GeneReviews reports 11/11 families with a clinically diagnosed phenotype had a pathogenic variant identified this way; targeted testing of the PCNA-binding-domain "hot spot" region is efficient given the tight mutational clustering - Multigene panels for growth restriction/adrenal hypoplasia differential (including CDKN1C, NR0B1, POLE1, SAMD9) - Exome/genome sequencing when the phenotype is atypical or overlaps other growth/adrenal disorders - Parent-of-origin (imprinting) testing/methylation studies may be relevant to confirm maternal transmission where pedigree information is ambiguous

Clinical criteria/differential diagnosis:

Screening: No population newborn-screening program exists (too rare, and adrenal insufficiency is not part of standard newborn screening panels such as 17-OHP-based CAH screening). Cascade/prenatal testing is offered in known-affected families once the pathogenic variant is identified (see Genetic Counseling above).

11. Outcome/Prognosis

• Survival/mortality: With prompt recognition and glucocorticoid/mineralocorticoid replacement, adrenal crisis is treatable and long-term survival into adulthood is achieved (oldest reported case: 26 years). Untreated/unrecognized adrenal crisis in the neonatal period is life-threatening and represents the principal acute mortality risk.
• Morbidity: Lifelong dependence on steroid replacement with attendant risks (adrenal crisis during intercurrent illness if stress-dosing is inadequate); skeletal complications (scoliosis, osteoporosis); renal complications (nephrocalcinosis) in a subset; urogenital surgical needs in males.
• Cognitive/functional outcome: Generally favorable — normal cognitive development reported in ~94% of assessed individuals (15/16), a notably reassuring prognostic feature relative to many other congenital syndromes.
• Reproductive outcome: Two affected females have reproduced; no affected males have reproduced, consistent with male hypogonadism.
• Neoplasia risk: Not established as an elevated cancer-predisposition syndrome analogous to the tumor-suppressor loss-of-function paradigm in Beckwith-Wiedemann syndrome (where CDKN1C loss-of-function contributes to embryonal tumor risk, e.g., Wilms tumor). However, a single case report of co-occurring rhabdomyosarcoma (PMID: 34098225) raises an open question about possible tumor association that has not been systematically studied given the tiny total case count — this should be flagged as a knowledge gap rather than an established risk.
• Prognostic factors: Timeliness of adrenal insufficiency diagnosis/treatment is the dominant modifiable prognostic factor; specific missense variant may influence phenotypic severity/spectrum (e.g., p.Arg279Leu/Ser giving a milder, non-adrenal Silver-Russell-like presentation).

12. Treatment

Pharmacotherapy (mainstay): - Acute adrenal crisis: IV isotonic saline, IV dextrose/glucose, and IV hydrocortisone (stress-dose glucocorticoid), with close monitoring of blood pressure, hydration status, and electrolytes; NCIT term: NCIT:C15986 (Pharmacotherapy), NCIT:C2924 (Corticosteroid, or specific NCIT:C328 Hydrocortisone) - Chronic maintenance: Physiologic glucocorticoid replacement (hydrocortisone) plus mineralocorticoid replacement (fludrocortisone) when needed; oral sodium chloride supplementation for salt-wasting - Stress dosing protocols: Increased glucocorticoid dose during illness, surgery, or trauma; MedicAlert bracelet strongly recommended for emergency recognition - Growth hormone therapy: Considered in selected cases with evidence of growth hormone deficiency/insufficient growth response - Testosterone replacement: For males with hypogonadotropic hypogonadism at expected puberty

Surgical/interventional: - Urologic surgery for cryptorchidism and hypospadias (NCIT:C15329, Surgical Procedure) - Orthopedic intervention for scoliosis or hip dysplasia as clinically indicated

Supportive/rehabilitative: - Occupational, speech, and physical therapy for hypotonia and any developmental delay (NCIT:C15302, Physical Therapy)

Experimental/targeted therapy: No gene therapy, RNA-based therapy, or molecularly targeted therapy specific to CDKN1C stabilization has been reported for IMAGe syndrome in the literature surveyed — management remains supportive/replacement-based rather than mechanism-correcting. No disease-specific registered clinical trials (ClinicalTrials.gov) were identified, consistent with the disorder's ultra-rare status.

Surveillance protocol (per GeneReviews): - Growth measurement at every visit - Annual endocrine evaluation of adrenal function; monitoring for hypercalciuria/nephrocalcinosis - Orthopedic evaluation as needed - Neurodevelopmental assessment at each visit

Treatment outcomes: Well-managed replacement therapy allows normal growth trajectories to be partially supported and prevents crisis-related mortality; no systematic response-rate or adverse-event data exist beyond general glucocorticoid/mineralocorticoid replacement pharmacology (well characterized in adrenal insufficiency literature generally, not disease-specific).

13. Prevention

• Primary prevention: Not applicable in the classic sense (this is a highly penetrant monogenic disorder) — the closest analog is reproductive/genetic counseling for at-risk families to inform reproductive decisions.
• Secondary prevention: Early recognition and prompt glucocorticoid/mineralocorticoid initiation in a neonate with IUGR plus biochemical signs of adrenal insufficiency prevents crisis-related morbidity/mortality — this is the single most impactful "preventive" intervention described.
• Genetic counseling: | Scenario | Recurrence risk | |---|---| | Child of affected/carrier mother | 50% | | Child of affected/carrier father | 50% chance of inheriting variant, but expected unaffected (imprinting) | | Sibling, mother confirmed carrier | 50% | | Sibling, mother tested negative | <1% (germline mosaicism possibility) |
• Prenatal testing and preimplantation genetic testing (PGT) are available once the familial pathogenic variant is known, offered as a personal reproductive decision (GeneReviews NBK190103).
• Screening: No population-level newborn screening exists; targeted cascade testing is the applicable "screening" modality in known families.
• Prophylaxis: Stress-dose glucocorticoid protocols function as prophylaxis against adrenal crisis during physiologic stress in already-diagnosed patients.

14. Other Species / Natural Disease

• No naturally occurring IMAGe syndrome has been reported in non-human species (companion animals, livestock, or wildlife); no OMIA (Online Mendelian Inheritance in Animals) entry was identified in this search.
• CDKN1C (p57^KIP2^) is evolutionarily conserved across mammals, and mouse Cdkn1c is the basis of the principal animal-model literature (see Section 15), but this reflects engineered laboratory models, not natural veterinary disease.
• No zoonotic or cross-species transmission relevance (monogenic, non-infectious disorder).

15. Model Organisms

Mouse (Mus musculus):* - Cdkn1c-null mice: Model the reciprocal, loss-of-function/BWS side of the allelic spectrum rather than IMAGe itself. Show ~20% fetal overgrowth followed by a late-gestation reversal, placental labyrinth thrombotic lesions, disordered trophoblast/sinusoidal giant-cell architecture, and high perinatal lethality (<10% survival to adulthood) (PMID: 21729874, Dis Model Mech 2011). - p57^Kip2^ Cdk-binding-domain knock-in mice: Used to dissect CDK-dependent versus CDK-independent p57 functions relevant to BWS pathogenesis (PMID: 27015986). - Gap identified: No CDKN1C PCNA-binding-domain (IMAGe-specific gain-of-function) knock-in mouse model was found in this search — an IMAGe-mimicking growth-restricted mouse model appears not yet reported in the literature surveyed, representing a HUMAN_MODEL_MISMATCH-relevant gap: existing Cdkn1c* mouse literature informs the opposite (loss-of-function/overgrowth) end of the phenotypic spectrum, and its translational relevance to the IMAGe gain-of-function mechanism should be treated cautiously if cited as supporting evidence for IMAGe-specific pathophysiology.

Drosophila melanogaster: - Transgenic eye-specific expression of IMAGe-mutant human CDKN1C (versus wild-type) produced significantly more severe eye growth defects, providing direct in vivo functional evidence for the gain-of-function mechanism outside a mammalian system (Nature Genetics, ng.2275, Arboleda et al. 2012).

Cell-based/in vitro systems: - Patient-derived and transfected mammalian cell lines used to measure p57^KIP2^ protein half-life, PCNA-binding, ubiquitination, and S-phase entry — the principal direct evidence base for the stabilization/gain-of-function mechanism (PMID: 24098681; PMID: 25861374). - POLE1-mutant patient fibroblasts: used to demonstrate delayed S-phase progression and aberrant nuclear localization/degradation of mutant Pol ε protein (PMID: 35534205).

Model limitations: The existing mouse literature captures BWS (loss-of-function) biology well but has not yet produced a validated IMAGe (gain-of-function) in vivo mammalian model; Drosophila and cell-based systems, while mechanistically informative, cannot recapitulate the tissue-specific human phenotypes (adrenal hypoplasia, male-specific genital anomalies) — this is an appropriate candidate for a HUMAN_MODEL_MISMATCH-style knowledge-gap annotation if curated into a mechanism-graph knowledge base, since the available fly/cell evidence supports the general gain-of-function/proliferation-inhibition mechanism but not the organ-specific developmental phenotypes.

Summary Table: Suggested Ontology Term Bindings for Curation

Sources

• GeneReviews: IMAGe Syndrome (NBK190103) — Schrier Vergano SA, Deardorff MA, updated 2021
• OMIM #614732
• OMIM #618336 (POLE1/IMAGe-I)
• MONDO:0013873
• Increased Protein Stability of CDKN1C Causes a Gain-of-Function Phenotype in Patients with IMAGe Syndrome, PLOS ONE (PMID 24098681)
• Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome, Nature Genetics
• Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing entry into S phase (PMID 25861374)
• IMAGe and Related Undergrowth Syndromes: The Complex Spectrum of Gain-of-Function CDKN1C Mutations (PMID 28508599)
• DNA Polymerase Epsilon Deficiency Causes IMAGe Syndrome with Variable Immunodeficiency, AJHG
• Novel POLE mutations identified in patients with IMAGE-I syndrome (PMID 35534205)
• A patient with polymerase E1 deficiency (POLE1) (PMC4630961)
• A case of an infant suspected as IMAGE syndrome finally diagnosed with MIRAGE syndrome (PMID 29506479)
• A Case report: Co-occurrence of IMAGe syndrome and Rhabdomyosarcoma (PMID 34098225)
• Is Hyperpigmentation on the First Day of Life Always Associated with IMAGe Syndrome? (PMC4293665)
• Fetal overgrowth in the Cdkn1c mouse model of Beckwith-Wiedemann syndrome (PMID 21729874)
• p57(Kip2) knock-in mouse reveals CDK-independent contribution in the development of BWS (PMID 27015986)
• An imprinted IMAGe: insights into growth regulation through genomic analysis of a rare disease (PMC3580416)
• Functional Versatility of the CDK Inhibitor p57Kip2 (PMC7575724)
• Deep exploration of a CDKN1C mutation causing a mixture of BWS and IMAGe syndromes (PMC8788247)
• An Intronic Variant in CDKN1C Gene Causing IMAGe Syndrome in an Iranian Girl (PMC12604900)
• MedlinePlus Genetics: IMAGe syndrome

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.